Semaglutide is a GLP-1 receptor agonist with clinical trial evidence for metabolic outcomes and authorized Canadian prescription products. Indications and product approvals are formulation-specific.
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied in major human clinical trials. Health Canada lists authorized prescription products, while unauthorized online copies require careful distinction.
An evidence-based guide to peptides researched for weight management, distinguishing authorized GLP-1-based medicines from experimental compounds and unapproved supplier claims.